Kura Oncology Company Insiders
KURA Stock | USD 21.33 0.16 0.76% |
Kura Oncology employs about 142 people. The company is managed by 27 executives with a total tenure of roughly 96 years, averaging almost 3.0 years of service per executive, having 5.26 employees per reported executive. Analysis of Kura Oncology's management performance can provide insight into the company performance.
Troy Wilson Chairman Chairman of the Board and Presidentident, CEO, Co-Founder |
Annette North President Senior Vice President General Counsel |
Kura |
Kura Oncology Management Team Effectiveness
The company has return on total asset (ROA) of (0.229) % which means that it has lost $0.229 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3734) %, meaning that it created substantial loss on money invested by shareholders. Kura Oncology's management efficiency ratios could be used to measure how well Kura Oncology manages its routine affairs as well as how well it operates its assets and liabilities.Kura Oncology Workforce Comparison
Kura Oncology is currently regarded as number one stock in number of employees category among related companies. The total workforce of Health Care industry is now estimated at about 38,902. Kura Oncology adds roughly 142 in number of employees claiming only tiny portion of equities under Health Care industry.
Kura Oncology Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Kura Oncology insiders, such as employees or executives, is commonly permitted as long as it does not rely on Kura Oncology's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Kura Oncology insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Dale Stephen over two weeks ago Disposition of 4825 shares by Dale Stephen of Kura Oncology at 21.5502 subject to Rule 16b-3 | ||
Troy Wilson over two months ago Exercise or conversion by Troy Wilson of 6945 shares of Kura Oncology subject to Rule 16b-3 | ||
Troy Wilson over three months ago Bona fide gift to Troy Wilson of 2000 shares of Kura Oncology subject to Section 16 | ||
Troy Wilson over six months ago Acquisition or disposition of Kura Oncology securities by Troy Wilson | ||
Troy Wilson over a year ago Acquisition or disposition of Kura Oncology securities by Troy Wilson |
Kura Oncology Notable Stakeholders
A Kura Oncology stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Kura Oncology often face trade-offs trying to please all of them. Kura Oncology's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Kura Oncology's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Liu Yi | Co-Founder, Chief Scientific Officer | Profile | |
Troy Wilson | Chairman of the Board and Presidentident, CEO, Co-Founder | Profile | |
Annette North | Senior Vice President General Counsel | Profile | |
Heidi Henson | CFO, Secretary | Profile | |
Marc Grasso | CFO and Chief Business Officer | Profile | |
John Farnam | COO | Profile | |
Pingda Ren | Sr. VP of Chemistry and Pharmaceutical Sciences | Profile | |
Steven Stein | Director | Profile | |
Thomas Malley | Director | Profile | |
Mary Szela | Director | Profile | |
Faheem Hasnain | Independent Director | Profile | |
Robert Hoffman | Independent Director | Profile | |
Maureen MBA | VP Management | Profile | |
Mollie MD | Executive Development | Profile | |
Francis Burrows | Senior Research | Profile | |
Roger Bakale | Clinical CMC | Profile | |
Marc MD | Advisor | Profile | |
Thomas Doyle | Principal Accounting | Profile | |
Esq JD | Chief Sec | Profile | |
MS MBA | Chief Officer | Profile | |
Kirsten Flowers | Chief Officer | Profile | |
Kathleen Ford | Chief Officer | Profile | |
JD Esq | Chief Secretary | Profile | |
Stephen MD | Chief Officer | Profile | |
Troy JD | CEO, Chairman | Profile | |
Antonio Gualberto | Chief Medical Officer | Profile | |
Pete Spain | Executive Communications | Profile |
About Kura Oncology Management Performance
The success or failure of an entity such as Kura Oncology often depends on how effective the management is. Kura Oncology management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Kura management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Kura management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California. Kura Oncology operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 123 people.
The data published in Kura Oncology's official financial statements usually reflect Kura Oncology's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Kura Oncology. For example, before you start analyzing numbers published by Kura accountants, it's critical to develop an understanding of what Kura Oncology's liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Kura Oncology's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Kura Oncology's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Kura Oncology's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Kura Oncology. Please utilize our Beneish M Score to check the likelihood of Kura Oncology's management manipulating its earnings.
Kura Oncology Workforce Analysis
Traditionally, organizations such as Kura Oncology use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Kura Oncology within its industry.Kura Oncology Manpower Efficiency
Return on Kura Oncology Manpower
Revenue Per Employee | 0.0 | |
Revenue Per Executive | 0.0 | |
Net Loss Per Employee | 1.1M | |
Net Loss Per Executive | 5.7M | |
Working Capital Per Employee | 2.8M | |
Working Capital Per Executive | 14.7M |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kura Oncology. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Kura Stock refer to our How to Trade Kura Stock guide.You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Complementary Tools for Kura Stock analysis
When running Kura Oncology's price analysis, check to measure Kura Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kura Oncology is operating at the current time. Most of Kura Oncology's value examination focuses on studying past and present price action to predict the probability of Kura Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kura Oncology's price. Additionally, you may evaluate how the addition of Kura Oncology to your portfolios can decrease your overall portfolio volatility.
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data |
Is Kura Oncology's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kura Oncology. If investors know Kura will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kura Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Kura Oncology is measured differently than its book value, which is the value of Kura that is recorded on the company's balance sheet. Investors also form their own opinion of Kura Oncology's value that differs from its market value or its book value, called intrinsic value, which is Kura Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kura Oncology's market value can be influenced by many factors that don't directly affect Kura Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kura Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Kura Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kura Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.